Atila PGx Neuropsychiatric SNP Panel (Psychiatry, CNS & ADHD)
Genotyping of 58 pharmacogenomic SNPs across 14 genes relevant to antidepressant, antipsychotic, and ADHD medication response and CNS risk.
Each kit includes 100 tests. This product is for Research Use Only (RUO).
Atila PGx Neuropsychiatric SNP Panel (Psychiatry, CNS & ADHD)
Psychiatric prescribing is a leading application of PGx. CYP2D6 and CYP2C19 metabolizer status shapes exposure to most SSRIs, TCAs, and many antipsychotics (CPIC guidelines), while receptor and transporter markers (HTR2A, HTR2C, DRD2, ANKK1, ADRA2A, SLC6A2, COMT, GRIK4) inform efficacy, tolerability, and antipsychotic-associated weight gain. APOE is included for CNS/Alzheimer risk context - a risk marker rather than a dosing guide.
Features Include
Technical Specs
Workflow Overview for the Atila PGx Neuropsychiatric SNP Panel (Psychiatry, CNS & ADHD)
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
Prepare the sample–master mix
For each sample, combine 2 µL of PCR master mix with 1 µL of genomic DNA to make a 3 µL-per-reaction mix. Scale the volume to the number of assay wells required for that sample.
Load the panel plate
Dispense the combined master mix–sample mixture into each assay well of the pre-arrayed panel plate. Seal the plate and briefly centrifuge to collect the reaction at the bottom of each well.
Run real-time PCR
Load the plate onto a Bio-Rad CFX or Applied Biosystems Quant Studio real-time PCR system and run the standard PCR cycling protocol.
Data analysis
Import the run file into the accompanying analysis software for automated allele calling and genotype determination across all panel SNPs.
Obtain result report
The software generates a structured pharmacogenetics report translating each genotype into gene-level phenotype and drug-response context.